8-K ·Filed Apr 8, 2026
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish
The lifting of the clinical hold is a positive regulatory development for lorigerlimab, potentially accelerating enrollment and data readout. Monitor for mid-year update on clinical progress.
Final — all horizons settled through T+60d ⚠ clustered
MGNX ▲ +32.85% at T+60d
LONG call ✓ call won +32.85% · α vs SPY +22.07% · entry $3.44 → $4.57
T+1d
+4.65%
call +4.65% · α +4.71%
$3.60
settled 6mo ago
T+5d
-0.87%
call -0.87% · α -4.06%
$3.41
settled 6mo ago
T+20d
-12.50%
call -12.50% · α -20.07%
$3.01
settled 5mo ago
T+60d
+32.85%
call +32.85% · α +22.07%
$4.57
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
MacroGenics announced that the FDA has lifted the partial clinical hold on its Phase 2 LINNET study of lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4, for gynecologic cancers. The company plans to resume enrollment and provide a mid-year program update.
Key Facts
- FDA removed partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab
- Study evaluates lorigerlimab in patients with platinum-resistant ovarian cancer or clear cell gynecologic cancer
- To date, 41 patients have been dosed in the LINNET study
- Company plans to resume enrollment and provide mid-year 2026 update
Financial Impact
Positive for clinical development progress
clinical developmentdrug pipelineregulatory progress
Risk Factors
- Potential for future safety issues to re-emerge
- Clinical efficacy may not meet expectations in ongoing trial
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001125345-26-000026 |
| Exhibit: exhibit991_linnetstudyhold.htm | 0001125345-26-000026 |
| Document: 0001125345-26-000026-index-headers.html | 0001125345-26-000026 |
| Document: 0001125345-26-000026-index.html | 0001125345-26-000026 |
| Document: 0001125345-26-000026.txt | 0001125345-26-000026 |
11 reports for MGNX
80% Hit rate best @ T+60▲ +130.41%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 8, 2026 12w ago | 8-K | $4.57 $4.01 | ▼ −12.25% | ▼ −14.50% | $3.58 (−21.66%) |
Jul 2, 2026 13w ago | Press Release | $4.71 $3.78 | ▼ −19.75% | ▼ −19.33% | $3.58 (−23.99%) |
Jun 12, 2026 16w ago | Institutional Cluster | $3.96 $4.33 | ▲ +9.34% | ▲ +7.56% | $3.58 (−9.60%) |
Jun 11, 2026 16w ago | Institutional Cluster | $4.01 $4.57 | ▲ +13.97% | ▲ +12.07% | $3.58 (−10.72%) |
May 13, 2026 20w ago | 8-K | $4.16 $3.96 | ▼ −4.81% | ▼ −3.95% | $3.58 (−13.94%) |
May 12, 2026 20w ago | 8-K | $3.52 $3.87 | ▲ +9.94% | ▲ +11.67% | $3.58 (+1.70%) |
May 11, 2026 20w ago | Press Release | $3.52 $3.87 | ▲ +9.94% | ▲ +11.67% | $3.58 (+1.70%) |
Apr 8, 2026 25w ago | 8-K | $3.44 $3.01 | ▼ −12.50% | ▼ −20.07% | $3.58 (+4.07%) |
Apr 8, 2026 25w ago | Press Release | $3.44 $3.01 | ▼ −12.50% | ▼ −20.07% | $3.58 (+4.07%) |
Apr 8, 2026 25w ago | DEFA14A | $3.44 $3.01 | ▼ −12.50% | ▼ −20.07% | $3.58 (+4.07%) |
Showing 10 of 11
US Market Status
Market Closed — Opens Mon (65h 6m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access